Abstract: The subject invention concerns a novel and useful insecticide with activity against insect pests of the order Lepidoptera. Pests in the order Lepidoptera do heavy damage to crops, e.g., cabbage and broccoli. The insecticide of the subject invention is a novel B. thuringiensis microbe referred to as B.t. PS85A1, or mutants thereof. Specifically disclosed is an asporogenous mutant designated B.t. PS85A1-168. The spores or crystals of B.t. PS85A1, or the crystals of B.t. PS85A1-168, are useful to control lepidopteran pests in various environments.

Abstract: The immune response of a patient can be improved pre-operatively by altering the diet of a patient. When 20 to about 80% of the calories in a diet are from linoleic acid which is an omega 6 fatty acid, the immune response system and resistance to infection of the patient is substantially improved. Likewise providing 100 to about 1,000 IU per day of vitamin E in the diet also improves the immune response of the patient pre-operatively. This in turn improves the survival rate of the patient.

Abstract: An enteral diet composition which comprises a balanced diet aqueous medium mixture of fat, carbohydrate, and dietary nitrogen compounds characterized by a total energy content of at least about 0.68 kcal/ml, an osmolality of below about 350 milli-osmol and a pH lower than about 4.5. The dietary nitrogen compounds are at least about 95% soluble in the aqueous medium and are free from bitterness in the composition. At least about 50% of the dietary nitrogen compounds is derived from vegetable protein source(s).The enteral diet product exhibits a combination of advantageous characteristics, i.e., good microbiological stability, good physical stability of the emulsion, low osmolality, satisfactory organoleptic properties, and satisfactory nutritional and handling properties.

Abstract: The present invention involves the inhibition of wound contraction by polypeptides having an amino acid sequence which is similar or identical to certain amino acid sequences of type (I) collagen. A variety of peptides are disclosed which are clinically useful as inhibitors of wound contraction.

Abstract: Methodology involving novel coupling reagents for the carboxyl-terminal amino acid sequence analysis of peptides and proteins is described.

Abstract: Collagen is submitted to a controlled oxidation by treatment with a solution of periodic acid or of a periodate, notably of sodium. Application to gels, implants, lenses, films, spheres, etc., of collagen.

Abstract: Disclosed herein are an anti-tumor substance obtained by bonding an anti-tumor agent to human immunoglobulin, and a process for producing the same.

Abstract: Cells or endospores of a butyric-acid bacterium Clostridium butyricum MII588-Sens 1 strain, or cells or endospores of a butyric-acid bacterium Clostridium butyricum MII588-Res 1 strain are effective as a biological intestinal antiseptic.

Abstract: A hemostatic collagen paste composition comprising a mixture, by weight of the total composition, of 2 to 30% of crosslinked collagen powder of 10 to 100 mesh particle size and 30 to 98% of water or an aqueous saline solution and hemostatic paste compositions that also comprise a hemostatic enhancing amount of thrombin, as well as methods of making and using such hemostatic collagen paste compositions.

Abstract: A cold water-soluble instantized gelatin having full gelation ability while containing no additives is obtained by spraying a pure gelatin solution without additives and having a water content of at least 35% at a temperature in excess of the gelation and solidification temperature on an excess of finely divided solid gelatin particles which contain less than 8% of water, and drying the particles thus obtained in a fluid bed to a water content of from 8 to 13%, whereupon a portion is removed from the process as final product and is further dried to a water content as required for optimum dissolution to occur in cold water, while the remainder first is more effectively dried to a water content below 8% and is then recycled into the process.

Abstract: Gel-free concentrated aqueous formulations of vancomycin hydrochloride are provided which comprise the antibiotic salt at a concentration between about 12% and about 50% w/v and a gel-inhibiting compound, e.g., ethanol, at a concentration between about 1% and about 20% v/v. The gel-free formulations are especially useful in a freeze-drying process for preparing vancomycin hydrochloride as a dry flowable powder in bulk or in unit-dosage form.